Cited by 402Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsNeurological Disease Mechanisms and Treatments

Formation and maintenance of Alzheimer's disease β-amyloid plaques in the absence of microglia

Open access
Grathwohl, Stefan A, Kälin, Roland E, Bolmont, Tristan, Prokop, Stefan, Winkelmann, Georg, Kaeser, Stephan A, Odenthal, Jörg, Radde, Rebecca +8 more·2009·Nature Neuroscience

Abstract

In Alzheimer's disease, microglia cluster around beta-amyloid deposits, suggesting that these cells are important for amyloid plaque formation, maintenance and/or clearance. We crossed two distinct APP transgenic mouse strains with CD11b-HSVTK mice, in which nearly complete ablation of microglia was achieved for up to 4 weeks after ganciclovir application. Neither amyloid plaque formation and maintenance nor amyloid-associated neuritic dystrophy depended on the presence of microglia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nn.2432

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • It remains unclear to what extent microglia are capable of removing amyloid from pre-existing fibrillar congophilic plaques or of preventing the deposition of smaller protofibrillar Aβ aggregates.

    “it remains unclear to what extent microglia are capable of removing amyloid from pre-existing fibrillar congophilic plaques (Stalder et al., 2001) or of preventing the deposition of smaller protofibrillar Aβ aggregates (Grathwohl et al., 2009).”

    From CX3CR1 in Microglia Regulates Brain Amyloid Deposition through Selective Protofibrillar Amyloid-β Phagocytosis (2010) · cites this paper as Grathwohl et al., 2009

    The citation to Grathwohl et al. attaches to the claim about preventing deposition of smaller protofibrillar Aβ aggregates, not to the preceding claim about removing pre-existing plaques. In the Introduction (page unavailable), the paper reports that microglial ablation did not prevent plaque formation or change the extent of Aβ deposition in APP mouse models. It does not specifically assess smaller protofibrillar aggregates, so it supports the broader uncertainty about microglia and deposition but not that specific form. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • Gancyclovir-mediated depletion of microglia expressing thymidine kinase had no demonstrable effect on Aβ pathology in two mouse models of AD.

    “Finally, a recent study provided evidence that gancyclovir-mediated depletion of microglia expressing thymidine kinase had no demonstrable effect on A␤ pathology in two mouse models of AD. 57”

    From CX3CR1 Deficiency Alters Microglial Activation and Reduces Beta-Amyloid Deposition in Two Alzheimer's Disease Mouse Models (2010) · cites this paper as [57]

    The Introduction reports no change in Aβ deposition or plaques after microglial depletion in APPPS1 mice. In the second model, APP23, it reports unchanged congophilic and vascular amyloid but a small reduction in total Aβ load, mainly from reduced diffuse amyloid. Thus, 'no demonstrable effect on Aβ pathology' overstates the result across both models. Page numbers are not provided in our copy. (LLM, conf=0.90)

    Experimental — accuracy not yet measured
  • Previous in vivo results range from showing that microglia are effective at phagocytosis of fibrillar amyloid to suggesting that microglia play no role in the control of amyloid deposition.

    “Previous in vivo results range from showing that microglia are effective at phagocytosis of fibrillar amyloid (Frautschy et al., 1991; Bacskai et al., 2002; Bolmont et al., 2008) to suggesting that microglia play no role in the control of amyloid deposition (Grathwohl et al., 2009).”
  • The formation and maintenance of β-amyloid plaques in amyloidosis models does not seem to be affected by CSF1R inhibition or other methods of microglia depletion.

    “Unlike with synapse loss, the formation and maintenance of β-amyloid plaques in amyloidosis models does not seem to be affected by CSF1R inhibition or other methods of microglia depletion (Grathwohl et al., 2009; Olmos-Alonso et al., 2016; Spangenberg et al., 2016).”

    From Microglia in Alzheimer’s disease (2018) · cites this paper as Grathwohl et al., 2009

  • Aβ clearance and plaque modulation/dynamics is unaffected following microglia surround plaques.

    “Despite this response, however, Aβ clearance and plaque modulation/dynamics is unaffected10–12”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Grathwohl, S. A., Kälin, R. E., Bolmont, T., Prokop, S., Winkelmann, G., Kaeser, S. A., Odenthal, J., Radde, R., Eldh, T., Gandy, S., Aguzzi, A., Staufenbiel, M., Mathews, P. M., Wolburg, H., Heppner, F. L., & Jucker, M.
Affiliations
  • Hertie Institute for Clinical Brain Research (DE)
  • Charité – Universitätsmedizin Berlin (DE)
  • German Center for Neurodegenerative Diseases (DE)
  • University of Tübingen (DE)
  • Icahn School of Medicine at Mount Sinai (US)
  • University Hospital Zurich (CH)
  • Novartis (Switzerland) (CH)
  • Nathan Kline Institute for Psychiatric Research (US)
Corresponding author
  • Heppner, Frank L
  • Jucker, Mathias
Venue
Nature Neuroscience
Published
2009-10-18
Volume
12
Issue
11
Pages
1361-1363
ISSN
  • 1097-6256 (ISSN-L)
  • 1546-1726
OpenAlex
W2066165659
Cited by
401
References
22
Citations by year
2026: 5 · 2025: 10 · 2024: 11 · 2023: 19 · 2022: 8 · 2021: 27 · 2020: 20 · 2019: 21 · 2018: 26 · 2017: 33 · 2016: 21 · 2015: 38 · 2014: 27 · 2013: 33 · 2012: 43
FWCI
22.61
Type
journal article
Language
en
Open access
Locations
  • Nature Neuroscience (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
  • Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
Funders
  • National Institute on Aging (P01AG010491, AG017617, P01AG017617)
  • National Institute of Neurological Disorders and Stroke (NS045205, R01NS045205, R01NS046006)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
Alzheimer's disease, amyloid plaques, microglia, ganciclovir, APP transgenic mice, neuritic dystrophy, plaque clearance, mouse models of Alzheimer's disease
MeSH terms
CD68 Molecule, Alzheimer Disease, Animals, Antiviral Agents, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Female, Gene Expression Regulation, Humans, Injections, Intra-Articular, Male, Mice, Transgenic, Mutation, Plague, Thymidine Kinase, Antigens, Differentiation, Myelomonocytic, Antigens, CD, Ganciclovir, Amyloid beta-Peptides, Microscopy, Immunoelectron, Amyloid beta-Protein Precursor, Microglia, Neuroaxonal Dystrophies, CD11b Antigen, Green Fluorescent Proteins, Mice, Presenilin-1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review